Zafgen, Inc. announced Wednesday the completed enrollment of ZAF-203, a Phase 2b clinical trial of beloranib in the treatment of patients with both severe obesity and type 2 diabetes.
The trial enrolled 152 patients across 16 locations in Australia.
"We're very pleased to announce that we have completed enrollment for our Phase 2b study in this high risk population of obese patients complicated by type 2 diabetes inadequately controlled by other agents," Thomas Hughes, CEO of Zafgen said. "We look forward to seeing the impact of beloranib treatment on body weight and glycemic control, among other endpoints. This study provides our first view of the drug's potential to provide changes in the range of those seen following bariatric surgery."
ZAF-203 is a Phase 2b clinical trial designed to determine the long-term weight loss benefits of MetAP2 inhibitor treatment with beloranib in patients with severe obesity complicated by type 2 diabetes.
"The baseline characteristics of patients in this trial meet our expectations,” Dennis Kim, chief medical officer of Zafgen, said. “The population being studied is poorly controlled, at high risk of developing serious medical complications, and in need of improved therapies providing clinically significant weight loss and glycemic control.”
The main expected endpoint is change in total body weight at six months of randomized treatment.